Umesh Masharani is an Endocrinology/Metabolic physician affiliated with University of California, San Francisco. OpenAlex indexes 146 publications with 7,338 citations (h-index 35); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
400 Parnassus Ave
San Francisco, CA 941432202
Telephone
415-353-2350Provider last certified this registry record 4 Aug 2023.
Clinical trials
- Chromium and Insulin Resistance
Sponsor: University of California, San Francisco
- Alpha Lipoic Acid and Insulin Resistance
Sponsor: University of California, San Francisco
- Paleolithic Diets vs T2D and Improvements in the Metabolic Syndrome
Sponsor: University of California, San Francisco
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
56.6%Insulin Analog20.5%Humalog Kwikpen U-10019%Lantus Solostar19%Tresiba Flextouch U-10010%Insulin Lispro Kwikpen U-1009%Basaglar Kwikpen U-1009%Novolog Flexpen8%Humalog5%Humalog Junior Kwikpen4%Fiasp3%Insulin Aspart Flexpen3%Toujeo Solostar3%Fiasp Flextouch3%Lyumjev2%Insulin Lispro2%Part D<11 patientsGLP-1 receptor agonist10.9%Ozempic82%Trulicity10%Mounjaro8%Part D<11 patients+ 7 more classes in this area
Hormonal (systemic)
21.1%l-Thyroxine17.6%Levothyroxine Sodium82%Synthroid14%Levoxyl3%Part D<11 patientsThyroid Hormone Synthesis Inhibitor3.5%Methimazole100%Part D≥21 patientsCardiovascular
21%Statin9.1%Rosuvastatin Calcium54%Atorvastatin Calcium39%Pravastatin Sodium6%Part D<11 patientsCalcium channel blocker3.2%Amlodipine Besylate65%Diltiazem 24hr Er (Cd)18%Felodipine Er17%Part D<11 patients+ 5 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 1992–2007 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- The Diabetes Technology Society Error Grid and Trend Accuracy Matrix for Glucose Monitors
Journal of Diabetes Science and Technology
2024 - Consensus Report on Glucagon-Like Peptide-1 Receptor Agonists as Adjunctive Treatment for Individuals With Type 1 Diabetes Using an Automated Insulin Delivery System
Journal of Diabetes Science and Technology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Kristine Yaffe, MD
University of California, San Francisco
Peter Carroll, MD
University of California, San Francisco
Mitchel Berger, MD
University of California, San Francisco
Elyse Foster, MD
University of California, San Francisco
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”